Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-03-19FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ICLUSIG (ponatinib hydrochloride) submitted by Takeda Pharmaceuticals America, Inc. The appr…
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients [Phase 1, Phase 2]
A phase 1/2 trial evaluated the safety and efficacy of bosutinib in combination with atezolizumab in adults with newly diagnosed chronic mye…
-
FDA approval · 2024-03-01FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GLEEVEC (imatinib mesylate) submitted by Novartis Pharmaceuticals Corporation. This action confi…
-
CLINICAL_TRIALS trial_result · 2024-02-08Clinical Trial Update: Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study [Phase 4]
Phase 4 trial update on allowing access to nilotinib for patients already receiving nilotinib in a Novartis-sponsored study; study status co…
-
FDA approval · 2024-02-06FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TASIGNA (nilotinib) submitted by Novartis, resulting in changes to the labeling under the supple…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-01-31Clinical Trial Update: CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant [Phase 1]
Phase 1 trial evaluating the CMV-MVA Triplex vaccine given to stem cell donors to prevent cytomegalovirus viremia in recipients of allogenei…
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy [Phase 2]
Phase 2 clinical trial update for MGTA-456 in high-risk hematologic malignancies; results were posted in 2024 and the study is currently act…
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia [Phase 1, Phase 2]
Phase 1/2 trial evaluating natural killer cells as part of donor stem cell transplantation for various myeloid leukemias and myelodysplastic…
-
FDA approval · 2024-01-05FDA Approved: IMATINIB MESYLATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application from Mylan Pharmaceuticals for imatinib mesylate, enabling a generic version to be marketed under AN…
-
FDA approval · 2023-12-05FDA Approved: PHYRAGO — Original Application (Cycle Pharmaceuticals Ltd)
The FDA approved PHYRAGO (dasatinib) from Cycle Pharmaceuticals Ltd under an original application. Dasatinib is indicated for Philadelphia c…
-
CLINICAL_TRIALS trial_result · 2023-11-29Clinical Trial Update: KISS Study: Kinase Inhibition With Sprycel Start up [Phase 2]
A Phase 2 clinical trial update for a study evaluating Sprycel (dasatinib) in Chronic Myeloid Leukemia led by the University of Auckland; cu…
-
FDA label_change · 2023-11-08FDA Approved: SCEMBLIX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for SCEMBLIX (asciminib) submitted by Novartis Pharmaceuticals Corporation. The action involves chan…
-
CLINICAL_TRIALS research · 2023-10-27Clinical Trial Update: Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
A completed observational study analyzing chronic myeloid leukemia treatment patterns and real-world outcomes in Hungary using national heal…
-
FDA approval · 2023-09-26FDA Approved: BOSULIF — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves BOSULIF (bosutinib) as the original application for Philadelphia chromosome-positive chronic myeloid leukemia in adults with re…
-
FDA approval · 2023-09-26FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Bosulif (bosutinib) from Pfizer Laboratories Div Pfizer Inc. This action updates the drug's …
-
CLINICAL_TRIALS trial_result · 2023-09-22Clinical Trial Update: Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia [Phase 2]
Phase 2 trial updates the use of low-dose dasatinib (50 mg daily) as first-line treatment for newly diagnosed chronic-phase chronic myeloid …
-
FDA approval · 2023-09-22FDA Approved: DASATINIB — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for dasatinib by Apotex Corp. The approval allows the generic product to be marketed.
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Allo HSCT Using RIC for Hematological Diseases [Phase 2]
Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for various hematologic dise…
-
FDA approval · 2023-08-16FDA Approved: IMATINIB — Supplemental Application (Dr.Reddy's Laboratories Inc)
FDA approved a supplemental application for Imatinib from Dr. Reddy's Laboratories Inc, resulting in regulatory approval for a change to the…
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II [Phase 1, Phase 2]
This Phase I/II clinical trial evaluated Interleukin-7 for T-cell recovery after haploidentical and cord blood stem cell transplantation and…
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning [Phase 2]
Phase 2 trial update on allogeneic transplantation using timed sequential busulfan and fludarabine conditioning for various hematologic mali…
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study [Phase 3]
A Phase 3 trial evaluating a tyrosine kinase inhibitor (TKI) with interferon alpha for chronic myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: Dasatinib Holiday for Improved Tolerability [Phase 3]
A Phase 3 clinical trial update reports dasatinib holiday strategies to improve tolerability in chronic myeloid leukemia.
-
FDA approval · 2023-04-20FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for BOSULIF (bosutinib) submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2023-04-03Clinical Trial Update: A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation [Phase 2]
A pivotal Phase 2 study evaluating HQP1351 in chronic myeloid leukemia in accelerated phase with T315I mutation; current status not provided…